Sanwa Kagaku Kenkyusho Co., Ltd.

Nippon Oil Fats Co., Ltd.

Kabushiki Kaisha Sanwa Kagaku Kenkyusho

Sawa Chemical Laboratory Co., Ltd.

Kiichi Sawai

Masayasu Kurono

Takahiko Mitani

Yasuaki Kondo

Ryoichi Unno

Naohisa Ninomiya

Toshinao Usui

Hiromoto Asai

Kyoichi Asano

Kenji Miura

Haruo Takahashi

Yoshiro Ishiwata

Takuji Yamaguchi

Hiromoto Kimura

Masato Fukushima

Hiroshi Ozawa

Yutaka Baba

Kenichi Tanaka

Noriaki Kato

Kuniharu Mizuno

Akira Matsubara

Naofumi Terada

Yukiharu Matsumoto

Makoto Sato

Mitsuru Oka

Tsunemasa Suzuki

Tomoo Suzuki

Juichi Awaya

Kazumasa Nakano

Takashi Ito

Takahito Jomori

Noboru Kuboyama

Syoji Yokochi

Akio Kojima

Kiyotaka Hirooka

Hisashi Michishita

Katsuya Fujimura

Eiji Furukawa

Takuji Kakigami

Shunji Natori

Yuji Hayashi

Toshiyuki Kouzaki

Masahiro Nakajima

Motohide Hayashi

Hideaki Ninomiya

Bunkichi Kato

Hiroyuki Ohwaki

Shizuo Uno

Yohei Kobayashi

Jun Takeda

Hiroo Imura

Naohiro Kanayama

Akira Tashita

Noboru Tomiya

Hiroshi Okada

Yoshiya Kondo

Noriyuki Iwata

Kaneo Yamada

Masatoshi Ban

Osamu Takehiro

Shinichi Ikeda

Keizo Anzai

Tadashi Kurachi

Masanori Nagabuchi

Bunichiro Yasui

Takashi Iida

Naoko Sugiura

Shinji Ogura

Kougaku Isogawa

Tamaki Ohtuka

Toshihiko Terao

Masami Kamiya

Yoshika Yasuda

Akihiro Morioka

Hiroyuki Oowaki

Takahiko Matani

Hideako Ninomiya

Hideo Yamamoto

Hiromiotu Asai

Yoshirou Ishiwata

Hidetsugu Saito

Keiko Hasegawa

Kazumi Niu

Shunshuke Ito

Takao Sugiyama

Masao Onishi

Kenji Hamase

Tunematu Suzuki

Yutaka Seino

Yukiya Tanaka

Shigeyoshi Nakamura

Mikio Minamitani

Masahiko Koketsu

Takashi Meguro

Sadaaki Iwamura

Masashi Taki

Takao Matumoto

Yoshinaru Tanaka

Yuichi Shiokawa

A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.

Potentiator for interferon and an antiviral activity-potentiating

A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:

Maillard reaction inhibitor

Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

Method of treating wart

A novel, eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84. A pharmaceutical composition containing the novel polymer is useful for preventing symptoms of an immune disease such as hepatitis or for curing such a disease.

3-oxygermylpropionic acid polymer, pharmaceutical composition containing

There is disclosed a compound shown by a formula of ##STR1## wherein R.sub.1 is a hydrogen atom alkyl group having 1-4 carbon atoms or acyl group having 1-4 carbon atoms: R.sub.2 and R.sub.3 are a hydrogen atom, alkyl group having 1-4 carbon atoms, phenyl radical, halogen atom, cyano radical, acyl group having 1-4 carbon atoms, nitro radical, alkoxy group having 1 or 2 carbon atoms, or substituted or non-substituted amino group, respectively; n is an integer of 1-3; and dotted line means a possible ring, and a salt thereof. The compound and salt bind with muscarinic receptor in brain to develop a powerful actuation thereof and thus those can be used as an effective ingredient for preventing and curing senile dementias, and more particularly Alzheimer's disease.

Compounds and use thereof

A method of enzymatically measuring hydrogen peroxide by developing a color with use of 3-methyl-2-benzothiazolinoehydrazone as a coupler and in combination with an oxidative color developing reagent with peroxidase, and a reagent therefor is described. Catalase is added to the 3-methyl-2-benzothiazolinonehydrazone reagent as a stabilizer and the reaction is carried out in the presence of ethylenediaminetetraacetic acid or an analogue thereof. The color developing reaction may be carried out in neutral or weak alkali conditions. A reagent is described which comprises a buffer, 3-methyl-2-benzothiazolinohydrazone, and catalase.

Method of enzymatically measuring hydrogen peroxide and reagent therefor

Process for the preparation of motilin-like polypeptide, a recombinant DNA therefor, and a plasmid, in which the recombinant DNA is inserted.

Process for the preparation of motilin-like polypeptide and expression

A readily absorbable type of motilin preparation containing a motilin-like active substance and a surface active agent is provided, in which the motilin-like active substance is mainly L-leucine-13-motilin-homoserine, and the surface active agent is selected from the group consisting of a bile salt, saponin and a polyethylene glycol higher-alcohol ether for nasal administration purposes and is a peptide lytic enzyme inhibitor for oral administration purposes.

Use of orally absorbable motilin preparations to enhance motility of

A process for the preparation of a polypeptide of the formula ##STR1## wherein A' is Pro, Gly, Asp or Ser; B' is Gly, Asn or Ser; C is Gln, Glu or Asp; D is Asn, Glu or Asp; X' is a residue of amino acid other than Met; E is Gln, Lys or Arg, and Y' is a residue of homoserine or homoserine-lactone, as well as a recombinant DNA and expression plasmid for preparing the polypeptide.

Motilin-like polypeptide and use thereof

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Hydantoin derivatives for treating complications of diabetes

Early diagnosis of mastitis or garget is carried out by measuring the concentration of 3-hydroxybutyric acid in milk. Used to this end is a reagent reacting with 3-hydroxybutyric acid to show a color at a concentration of 100 .mu.mol/l or higher.

Early diagnosis of mastitis or garget

An aromatic amino-substituted compound represented by formula: ##STR1## wherein A represents CH, N, or N.fwdarw.O; R.sub.1 represents a nitro group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, or an acyl group; and R.sub.3 represents a group: ##STR2## wherein m represents 0 or 1; n represents an integer of from 0 to 3; R.sub.4 and R.sub.5 each represents a hydrogen atom or a lower alkyl group; R.sub.6 and R.sub.7 each represents a hydrogen atom or a straight chain or branched lower alkyl group; R.sub.4 and R.sub.6 may be joined together to form an alkylene chain forming a heterocyclic ring; R.sub.5 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring and R.sub.6 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring,

Nootropic agents, compositions of, and method of use thereof

A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.3 are each an amino acid residue having a side-chain with an aromatic ring, C is Gln, Glu or Asp, D is Asn, Glu or Asp, X' is an amino acid residue other than Met, E is Gln, Lys or Arg, and Y is homoserine, homoserine-lactone or a peptide chain having amino acid residues not exceeding 10 and containing homoserine or homoserine-lactone at the C-terminal where the first amino acid of said peptide chain is other than Lys, Arg or Pro.

Motlin-like polypeptide and use thereof

Vasoactive intestinal polypeptide (VIP) analogues and use thereof are disclosed. The VIP analogues are shown by the formula of

Vasoactive intestinal polypeptide analogues and use thereof

There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.

Pharmaceutical preparation containing vasoactive intestinal polypeptide

Growing community of inventors

Nagoya, Japan

Kiichi Sawai